α-Eleostearic Acid as a Senolytic Therapy - Quick Reference Sheet
evipedia.ai ← Back

α-Eleostearic Acid as a Senolytic Therapy

Created on 08/12/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A plant fat from bitter melon seeds that appears to kill worn-out cells by exploiting their higher iron and their oxidation-prone content. All evidence comes from cells and rodents; no human study has measured cell clearance. Main concerns: a narrow gap between killing worn-out and healthy cells, gut irritation, and evidence from commercially interested groups. (Full Review)

Protocol

Anchor dose from the only human trial
4.5 g bitter melon seed oil daily
Nine capsules delivering 2.3 g α-eleostearic acid, for 12 weeks in overweight adults aged 20–64
Split rather than single dosing
Divided across three meals
The human precedent divided 4.5 g across three meals, which both reduces gut irritation and matches the compound's slow, fat-dependent absorption
Best time of day
With the largest meal
Absorption is slow and lipid-dependent, and food reduces gut irritation; no circadian data exist for this compound
Time to effect
Senescence markers
7 days in mice
Senescence markers fell in mouse tissue within seven days; unknown in humans
Metabolic endpoints
4–12 weeks
Measured at 4, 8 and 12 weeks in the human trial, so weeks rather than days is the realistic expectation
Composite aging symptoms
6 weeks in mice
Score fell significantly over six weeks of dosing in prematurely aged mice, with the separation lost by week 16

Benefits

Contraindications
  • Pregnancy and lactation
  • Hereditary hemochromatosis or transfusional iron overload with ferritin above 300 ng/mL
  • Established pulmonary arterial hypertension, or World Health Organization functional class III–IV pulmonary vascular disease
  • Glucose-6-phosphate dehydrogenase deficiency
  • Decompensated liver disease, Child-Pugh Class B or C
  • Tung oil, tung nuts or Aleurites fordii material in any amount as a source
    •
Key Interactions
  • Iron supplements and iron-fortified foods
  • Iron chelators (deferoxamine, deferasirox, deferiprone)
  • High-dose vitamin E and other lipid-soluble antioxidants (α-tocopherol, coenzyme Q10, astaxanthin)
  • N-acetylcysteine and glutathione precursors
  • Lipoxygenase inhibitors (zileuton) and non-steroidal anti-inflammatory drugs (ibuprofen, naproxen)
  • Statins (cholesterol-lowering drugs such as atorvastatin and rosuvastatin)
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, aspirin, clopidogrel)
  • Other senolytics (dasatinib plus quercetin, fisetin, navitoclax)
  • Bitter melon fruit extracts and glucose-lowering drugs
    •

Risk & Side Effects

  • Medium: Gastrointestinal irritation and laxative effect; non-selective ferroptosis in healthy cells; oxidative burden and rancidity of the delivered oil
  • Low: Loss of beneficial senescent cells; adipose tissue inflammation and cell death; metabolic effects of the conversion product

Monitoring

Marker Target Why
Serum ferritin 50–150 ng/mL Iron substrate for the mechanism; screens for overload
Transferrin saturation 25–35% Free iron available to drive lipid peroxidation
Alanine aminotransferase (ALT) Under 25 U/L (men), under 20 U/L (women) Liver is where the fat is converted and stored
Gamma-glutamyl transferase (GGT) Under 20 U/L Oxidative stress and biliary load marker
High-sensitivity C-reactive protein Under 0.5 mg/L Primary readout of reduced inflammatory secretion from senescent cells
Fasting insulin and HOMA-IR Insulin under 6 μIU/mL; HOMA-IR under 1.5 Detects the metabolic effect and any adverse shift from the conversion product
Fasting triglycerides Under 80 mg/dL Tracks the liver-fat and fat-burning arm
Complete blood count with reticulocytes Hemoglobin stable versus own baseline; reticulocytes 0.5–2.0% Screens for oxidative damage to red cells
Plasma α-tocopherol 12–20 μmol/L, or stable versus own baseline The main brake on the mechanism; very high levels may nullify the effect
Oxidized low-density lipoprotein No established target for this use; track change from own baseline Direct readout of systemic lipid peroxidation burden

Cadence: Baseline panel before starting; liver panel and iron studies repeated at 4 and 12 weeks, then every 6 months if use continues; inflammatory and metabolic markers at 12 weeks, then every 6–12 months

Qualitative Assessment

  • Gastrointestinal comfort — stool frequency and form, since irritation is the earliest and commonest signal
  • Exercise recovery and perceived endurance, the one functional domain with a supporting animal signal
  • Skin quality and wound healing, plausible readouts of reduced local senescent-cell burden
  • Joint stiffness on waking, a lay proxy for the inflammatory secretions this class targets
  • Energy and cognitive clarity, tracked weekly rather than daily to avoid over-reading normal variation
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.